The article describes the discovery and development of compound 8e, a selective and reversible butyrylcholinesterase (BuChE) inhibitor, as a potential therapeutic agent for treating Alzheimer's disease (AD). Compound 8e exhibited favorable blood-brain barrier permeability, good drug-likeness properties, and pronounced neuroprotective efficacy in various AD models, including zebrafish, scopolamine-induced mice, and APP/PS1 transgenic mice.